Mary Anne Heino Sells 53,107 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock

Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the transaction, the director now owns 440,399 shares of the company's stock, valued at $41,551,645.65. This represents a 10.76 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Lantheus Stock Up 6.1 %

Lantheus stock traded up $6.11 during mid-day trading on Friday, hitting $106.34. 1,369,851 shares of the company's stock traded hands, compared to its average volume of 921,738. The firm has a 50 day moving average price of $90.71 and a 200 day moving average price of $96.85. The company has a market cap of $7.28 billion, a PE ratio of 17.69 and a beta of 0.38. Lantheus Holdings, Inc. has a one year low of $56.44 and a one year high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. On average, analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Remove Ads

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. The Goldman Sachs Group assumed coverage on Lantheus in a research report on Wednesday, December 18th. They set a "buy" rating and a $143.00 price objective for the company. Truist Financial boosted their price objective on Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. JMP Securities restated a "market outperform" rating and set a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. Finally, StockNews.com lowered Lantheus from a "buy" rating to a "hold" rating in a research report on Thursday, November 21st. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $132.86.

Institutional Trading of Lantheus

A number of hedge funds and other institutional investors have recently modified their holdings of LNTH. Wilmington Savings Fund Society FSB bought a new stake in shares of Lantheus in the 3rd quarter worth $25,000. Kestra Investment Management LLC bought a new stake in shares of Lantheus in the 4th quarter worth $27,000. Summit Securities Group LLC acquired a new stake in shares of Lantheus during the fourth quarter worth $37,000. UMB Bank n.a. raised its position in shares of Lantheus by 31.5% during the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after purchasing an additional 134 shares during the period. Finally, World Investment Advisors LLC acquired a new stake in shares of Lantheus during the third quarter worth $60,000. Institutional investors own 99.06% of the company's stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.